DITTO Raises $6M for Science-Driven Menstrual Health Solutions

DITTO, a company dedicated to advancing menstrual health through rigorous scientific inquiry and precisely formulated supplements, has successfully closed a $6 million Seed funding round. This capital infusion is earmarked to propel the company's research initiatives, broaden its portfolio of science-backed nutritional products, and extend its market presence. The funding round was spearheaded by FoodLabs, with significant participation from existing investor EKA Ventures and a cohort of private angel investors.

The menstrual health sector, historically underserved by dedicated research and often characterized by dismissive patient experiences, is ripe for innovation. DITTO aims to bridge this gap by conducting its own research, translating complex scientific findings into accessible information, and developing targeted solutions. The company's approach integrates neuroscience and nutritional science, focusing on evidence-based interventions for conditions like Premenstrual Syndrome (PMS) and the more severe Premenstrual Dysphoric Disorder (PMDD).

Founded in 2024 by neuroscientist Alice van der Schoot and former L'Oréal Brand Director Adam Kugler, DITTO positions itself at the nexus of scientific validation, community engagement, and effective product development. Their flagship supplement, Premenstrual Daily, is designed for proactive use, aiming to build physiological and neurological resilience against hormonal fluctuations before symptoms manifest. The formulation leverages advanced nutrient delivery technology to enhance absorption, a critical factor in the efficacy of dietary supplements.

DITTO reports promising results from its initial clinical trials, with 88% of participants experiencing significant symptom reduction. The company is currently undertaking larger-scale clinical trials and real-world evidence studies to further validate its formulations. Beyond its product development, DITTO is also investigating under-researched areas, including a systematic review exploring the connections between PMDD and ADHD, underscoring its commitment to comprehensive menstrual health research.

Flo Breiner, Operating Partner at FoodLabs, highlighted DITTO's unique position as a research-driven entity in the burgeoning femtech market. "Clinical evidence is rapidly becoming the benchmark for credibility in menstrual health," Breiner stated. "DITTO is establishing that standard with its proprietary delivery technology, a substantial community of over 300,000 women, and impressive customer loyalty." This strategic investment underscores the growing investor confidence in science-first approaches to women's health solutions.

The market for women's health solutions is experiencing significant growth, driven by increased awareness and a demand for evidence-based products. The global femtech market is projected to reach tens of billions of dollars in the coming years, with menstrual health representing a substantial segment. DITTO's focus on scientific validation and community building positions it to capture a significant share of this expanding market, offering a much-needed alternative to generic wellness products.